2020
DOI: 10.1007/978-981-15-4431-6_8
|View full text |Cite
|
Sign up to set email alerts
|

Overview of Early Detection of Gastrointestinal Cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(3 citation statements)
references
References 58 publications
0
3
0
Order By: Relevance
“…Several meta-analyses have demonstrated an association between the presence of GC CTCs and advanced tumor stage, lymphatic invasion, and poorer survival [ 29 ]. There are various markers for gastric cancer CTCs; for the epithelial subtype, they include EpCAm, cytokeratin (CK): CK8, CK18, and CK19 and for the mesenchymal subtype, they include vimentin and twist [ 30 , 31 ]. Another interesting marker for gastric cancer CTCs is fluorescence in situ hybridization (FISH) detection of CTCs with chromosome 8 aneuploidy, a mutation commonly found in gastric tumor cells [ 32 ].…”
Section: Diagnosismentioning
confidence: 99%
“…Several meta-analyses have demonstrated an association between the presence of GC CTCs and advanced tumor stage, lymphatic invasion, and poorer survival [ 29 ]. There are various markers for gastric cancer CTCs; for the epithelial subtype, they include EpCAm, cytokeratin (CK): CK8, CK18, and CK19 and for the mesenchymal subtype, they include vimentin and twist [ 30 , 31 ]. Another interesting marker for gastric cancer CTCs is fluorescence in situ hybridization (FISH) detection of CTCs with chromosome 8 aneuploidy, a mutation commonly found in gastric tumor cells [ 32 ].…”
Section: Diagnosismentioning
confidence: 99%
“…Although various treatment strategies can be applied [19], the overall survival rate remains low in advanced disease stages, presenting an urgent need for new diagnostic and therapeutic markers [20].…”
Section: Introductionmentioning
confidence: 99%
“…In recent years, the number of patients suffering from GI cancers has gradually increased (about 5 million patients in 2018), resulting in a higher mortality rate (approximately 3.5 million), which makes these malignancies a major cause of cancer‐related deaths worldwide [18]. Although various treatment strategies can be applied [19], the overall survival rate remains low in advanced disease stages, presenting an urgent need for new diagnostic and therapeutic markers [20].…”
Section: Introductionmentioning
confidence: 99%